[Biological effect of endostatin on transplanted human lung adenocarcinoma Calu-6 tumor in nude mice].
OBJECTIVE
To assess the effect of endostatin on growth and neoplastic angiogenesis in transplanted human lung adenocarcinoma Calu-6 tumor in nude mice.


METHODS
To treat Calu-6 tumor-bearing mice with endostatin at different doses, and to record the changes of the tumor size. The expressions of survivin, VEGF, COX-2 and MVD in tumor tissue were examined by immunohistochemistry staining, circulating endothelial cells (CECs) by flow cytometry and mRNA of CD146 and CD105 by RT-PCR and real-time PCR.


RESULTS
After endostatin treatment, the tumor size was conspicuously shrunk, and the expressions of survivin, COX-2 and VEGF protein and MVD in tumor tissue decreased concomitantly with the significant difference between each of trial groups and control group (all P < 0.05). Both CECs and mRNA of CD146 and CD105 diminished remarkably. A positive correlation between both exhibition and change of amount of activated CECs and survivin, VEGF expression and MVD count in tumor tissue was found.


CONCLUSIONS
Endostatin can decrease the expression of survivin, COX-2, VEGF and MVD, and to inhibit the growth of transplanted tumor. Activated CECs may probably serve as an ideal marker to predict the efficacy and prognosis of anti-angiogenesis therapy.
Wang
Jing
J
Key Laboratory of Cancer Prevention and Therapy, Lung Cancer Center, Department of Medical Oncology, Affiliated Cancer Hospital, Tianjin Medical University, Tianjin 300060, China.
Huang
Chun
C
Wei
Xi-Yin
XY
Zhan
Zhong-Li
ZL
Sun
Hui
H
Yang
Yi
Y
Li
Kai
K
D000230:Adenocarcinoma / Q000473:pathology; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D051929:CD146 Antigen / Q000378:metabolism; D045744:Cell Line, Tumor; D051546:Cyclooxygenase 2 / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D000071063:Endoglin; D043169:Endostatins / Q000008:administration & dosage / Q000494:pharmacology*; D042783:Endothelial Cells / Q000473:pathology; D005260:Female; D006801:Humans; D051034:Inhibitor of Apoptosis Proteins; D008175:Lung Neoplasms / Q000378:metabolism / Q000473:pathology*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D008869:Microtubule-Associated Proteins / Q000378:metabolism; D055806:Microvessels / Q000473:pathology; D009368:Neoplasm Transplantation; D012333:RNA, Messenger / Q000378:metabolism; D011897:Random Allocation; D011956:Receptors, Cell Surface / Q000378:metabolism; D000077022:Survivin; D047368:Tumor Burden / Q000187:drug effects*; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D015703:Antigens, CD; D000970:Antineoplastic Agents; C107489:BIRC5 protein, human; D051929:CD146 Antigen; C064206:ENG protein, human; D000071063:Endoglin; D043169:Endostatins; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D012333:RNA, Messenger; D011956:Receptors, Cell Surface; D000077022:Survivin; D042461:Vascular Endothelial Growth Factor A; D051546:Cyclooxygenase 2